Table 1

Baseline characteristics for survivors and non-survivors

Entire group (n = 517)Died (n = 103)Survived (n = 413)p Value
Median (range) follow up (months)23 (0 to 128)19 (0 to 122)23 (0 to 128)0.18
Demographics
Sex (M/F)367/15083/20281/1320.01
Age (years) (mean (SD))63.9 (10.1)65.7 (10.6)63.5 (9.9)0.07
Clinical presentation
Duration of angina (years) (mean (SD))8.1 (6.3)8.1 (6.1)8.0 (6.4)0.90
NYHA class (mean (SD))3.5 (0.7)3.5 (0.8)3.3 (0.6 )0.45
Cardiovascular status
LVEF ⩽40%24%44%19%< 0.01
Previous MI66%78%63%< 0.01
Three vessel disease68%82%64%< 0.01
PTCA17%8%18%0.02
CABG58%60%57%0.64
Risk factors
Family history of CAD61%66%59%0.50
Hypertension39%45%37%0.16
Hypercholesterolaemia28%26%29%0.60
Smoking21%24%21%0.58
IDDM14%20%13%0.05
Drug treatment
Calcium channel blockers73%76%73%0.46
β Blockers66%56%69%0.02
ACE inhibitors25%29%23%0.30
Short acting nitrates95%92%95%0.23
Long acting nitrates79%79%79%1.00
  • p Values were obtained by univariate analysis: two tailed Fisher’s exact test for discrete and Student’s ttest or Mann Whitney U test for continous variables.

  • ACE, angiotensin converting enzyme; CABG, coronary artery bypass graft surgery; CAD, coronary artery disease; IDDM, insulin dependent diabetes mellitus; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association functional class; PTCA, percutaneous transluminal coronary angioplasty.